---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-112848"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:33:30.881836+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bicycle Therapeutics reports Q3 net loss $50.8M; strong cash $890.9M; 45% ORR for zelenectide pevedotin

## Summary
- Net loss $50.8M ($0.74/shr) in Q3 2024 vs $49.9M ($1.26/shr) in Q3 2023; R&D spend $48.3M, up from $39.9M.
- Cash $890.9M as of Sep 30, 2024, up from $526.4M at Dec 31, 2023; expects cash runway into 2H 2027; $31.7M UK tax credit received Oct 2024.
- Zelenectide pevedotin (Nectin-4 BTC) monotherapy: 45% ORR in mUC (n=38), median DOR 11.1 months; differentiated safety profile; Phase 2/3 Duravelo-2 enrolling.
- BT5528 (EphA2 BTC) monotherapy: 45% ORR in mUC at 6.5 mg/m2 Q2W (n=11); low peripheral neuropathy rates; combo with nivolumab expected 2025.
- First human imaging data for BRC targeting MT1-MMP validates target; selected EphA2 as second BRC target; signed LOI with Eckert & Ziegler.

## SEC filing metadata
- accession: 0001104659-24-112848
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465924112848/0001104659-24-112848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465924112848/tm2426652d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-112848
- JSON: https://secwatch.observer/filing/0001104659-24-112848.json
- Plain text: https://secwatch.observer/filing/0001104659-24-112848.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.